Abstract
During embryogenesis there is an exquisite orchestration of cellular division, movement, differentiation, and death. Cell death is one of the most important aspects of organization of the developing embryo, as alteration in timing, level, or pattern of cell death can lead to developmental anomalies. Cell death shapes the embryo and defines the eventual functions of the organs. Cells die using different paths; understanding which path a dying cell takes helps us define the signals that regulate the fate of the cell. Our understanding of cell death in development stems from a number of observations indicating genetic regulation of the death process. With todays increased knowledge of the pathways of cell death and the identification of the genes whose products regulate the pathways we know that, although elimination of some of these gene products has no developmental phenotype, alteration of several others has profound effects. In this review we discuss the types and distributions of cell death seen in developing mammalian embryos as well as the gene products that may regulate the process.
Keywords: Programmed Cell Death, Embryonic Development, Apoptosis, Necrosis, Autophagy
Current Pharmaceutical Design
Title: Cell Death in Mammalian Development
Volume: 14 Issue: 2
Author(s): Z. Zakeri, C. Penaloza, S. Orlanski, Y. Ye, T. Entezari-Zaher and M. Javdan
Affiliation:
Keywords: Programmed Cell Death, Embryonic Development, Apoptosis, Necrosis, Autophagy
Abstract: During embryogenesis there is an exquisite orchestration of cellular division, movement, differentiation, and death. Cell death is one of the most important aspects of organization of the developing embryo, as alteration in timing, level, or pattern of cell death can lead to developmental anomalies. Cell death shapes the embryo and defines the eventual functions of the organs. Cells die using different paths; understanding which path a dying cell takes helps us define the signals that regulate the fate of the cell. Our understanding of cell death in development stems from a number of observations indicating genetic regulation of the death process. With todays increased knowledge of the pathways of cell death and the identification of the genes whose products regulate the pathways we know that, although elimination of some of these gene products has no developmental phenotype, alteration of several others has profound effects. In this review we discuss the types and distributions of cell death seen in developing mammalian embryos as well as the gene products that may regulate the process.
Export Options
About this article
Cite this article as:
Zakeri Z., Penaloza C., Orlanski S., Ye Y., Entezari-Zaher T. and Javdan M., Cell Death in Mammalian Development, Current Pharmaceutical Design 2008; 14 (2) . https://dx.doi.org/10.2174/138161208783378789
DOI https://dx.doi.org/10.2174/138161208783378789 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Neuroprotective Effects of Purslane (Portulaca oleracea) on Rotenone- Induced Biochemical Changes and Apoptosis in Brain of Rat
CNS & Neurological Disorders - Drug Targets Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) Effect of Withania somnifera Supplementation on Rotenone-Induced Oxidative Damage in Cerebellum and Striatum of the Male Mice Brain
Central Nervous System Agents in Medicinal Chemistry Alternative Splicing and Tumor Progression
Current Genomics Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Activin and TGF-β Effects on Brain Development and Neural Stem Cells
CNS & Neurological Disorders - Drug Targets miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Regulation of Autophagy in Oxygen-Dependent Cellular Stress
Current Pharmaceutical Design Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets Impaired Quality Control of Mitochondria Underlying the Pathogenesis of Alzheimer's Disease
Current Drug Targets Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology New Classes of AChE Inhibitors with Additional Pharmacological Effects of Interest for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Possible Use of Autologous Stem Cell Therapies for Alzheimers Disease
Current Alzheimer Research Cyclization in Opioid Peptides
Current Drug Targets Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design